WO1995009002A1 - Methode d'inhibition de la phagocytose - Google Patents
Methode d'inhibition de la phagocytose Download PDFInfo
- Publication number
- WO1995009002A1 WO1995009002A1 PCT/US1994/011108 US9411108W WO9509002A1 WO 1995009002 A1 WO1995009002 A1 WO 1995009002A1 US 9411108 W US9411108 W US 9411108W WO 9509002 A1 WO9509002 A1 WO 9509002A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor
- cells
- cell
- sequence
- immune complexes
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 64
- 206010057249 Phagocytosis Diseases 0.000 title claims abstract description 42
- 230000008782 phagocytosis Effects 0.000 title claims abstract description 42
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 28
- 102000009109 Fc receptors Human genes 0.000 claims abstract description 65
- 108010087819 Fc receptors Proteins 0.000 claims abstract description 65
- 230000004913 activation Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 131
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 51
- 102000005962 receptors Human genes 0.000 claims description 41
- 108020003175 receptors Proteins 0.000 claims description 41
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 32
- 108010073807 IgG Receptors Proteins 0.000 claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 230000001086 cytosolic effect Effects 0.000 claims description 22
- 230000000242 pagocytic effect Effects 0.000 claims description 20
- 239000012528 membrane Substances 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 14
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 13
- 108090000994 Catalytic RNA Proteins 0.000 claims description 12
- 102000053642 Catalytic RNA Human genes 0.000 claims description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 12
- 108091092562 ribozyme Proteins 0.000 claims description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 10
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 10
- 102000009490 IgG Receptors Human genes 0.000 claims description 10
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 230000019491 signal transduction Effects 0.000 claims description 9
- 230000000692 anti-sense effect Effects 0.000 claims description 8
- 210000003630 histaminocyte Anatomy 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- 210000001616 monocyte Anatomy 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 4
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 210000001539 phagocyte Anatomy 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 102000009438 IgE Receptors Human genes 0.000 claims description 3
- 108010073816 IgE Receptors Proteins 0.000 claims description 3
- 108091023045 Untranslated Region Proteins 0.000 claims description 3
- 230000000451 tissue damage Effects 0.000 claims description 2
- 231100000827 tissue damage Toxicity 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000003993 interaction Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 230000010799 Receptor Interactions Effects 0.000 abstract 1
- 230000009830 antibody antigen interaction Effects 0.000 abstract 1
- 230000037189 immune system physiology Effects 0.000 abstract 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 24
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 21
- 235000002374 tyrosine Nutrition 0.000 description 19
- 230000026731 phosphorylation Effects 0.000 description 17
- 238000006366 phosphorylation reaction Methods 0.000 description 17
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 10
- 101150110875 Syk gene Proteins 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 150000003668 tyrosines Chemical group 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- 238000000021 kinase assay Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 5
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229950006137 dexfosfoserine Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001845 splenic macrophage Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- VTJXFTPMFYAJJU-UHFFFAOYSA-N 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile Chemical compound OC1=CC=C(C=C(C#N)C#N)C=C1O VTJXFTPMFYAJJU-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010056838 PTK72 Proteins 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000773293 Rappaport Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 101150034785 gamma gene Proteins 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 210000003547 hepatic macrophage Anatomy 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000010865 video microscopy Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates, in general, to methods of treating diseases resulting from
- the present invention relates to methods of modulating the clearance of antibody-coated cells, viruses, or soluble antigens by inhibiting
- the invention also relates to the moduclation of those immune reactions for which the reaction of antigen-antibody complexes with Fc
- Certain immunological disorders are characterized by a disturbance in the expression of monocyte or macrophage Fc (IgG) receptors.
- An increase in the number of Fc receptors can result from an increase in the level of Fc receptor mediators such as gamma interferon or infection or the release of bacterial products.
- a decrease in the number of Fc receptors that can bind IgG can result not only from a reduction in the actual number of functional receptors but also from the saturation of Fc receptors by immune
- autoimmune diseases such as systemic lupus erythematosus
- levels of circulating immune complexes can be high and thus receptor
- autoimmune diseases the body's mechanisms for distinguishing between itself and foreign invaders malfunction.
- the body begins to make antibodies to certain parts of itself; these antibodies trigger the immune system which then destroys the tissue identified by the abnormal antibodies.
- autoimmune hemolytic anemias represent a group of disorders in which individuals produce
- erythrocytes to one or more of their own erythrocyte membrane antigens. Coating of erythrocytes by the abnormal antibodies is followed by their clearance from the circulation by splenic macrophages and subsequent destruction in the spleen.
- Representative diseases in this class are immune hemolytic anemia, immune
- autoimmune disease Another type of autoimmune disease is the type
- rheumatoid arthritis In these diseases, chronic inflammation is present in the joints, tendons, kidneys, lung, heart and other organs. In rheumatoid arthritis, for example, breakdown of joint cartilage into the synovial fluid of the joint is present in later stages of the disease. In systemic lupus
- Fc receptors recognition of these complexes in tissues by cells having Fc receptors initiates or increases tissue destruction by macrophages and possibly other cells such as polymorphonuclear leukocytes in these tissues. Reaction with these Fc receptors initiates a range of immune-associated reactions that may harm body tissues in proximity to these Fc receptor bearing cells.
- receptors are often treated with corticosteroids, or immunosuppressants. These treatments can have diverse and serious side effects.
- the present invention offers alternative treatment approaches that can be used alone or in combination with more conventional drug
- the present invention relates to a method of preventing the phagocytosis of immune complexes (eg IgG-containing immune complexes) and/or the release of intracellular biologically active products by cells interacting with immune complexes.
- An example of the present method comprises introducing into phagocytic cells of the mammal that are in contact with the immune complexes (eg, IgG-containing immune complexes) an inhibitor of a kinase endogenous to the cells that activates an Fc receptor present at the membrane of the cells.
- the present invention relates to a method of preventing the clearance of immune complexes (eg, IgG-containing immune complexes) from a mammal that comprises introducing into
- hematopoietic cells eg phagocytic cells
- the immune complex eg phagocytic cells of the mammal that are in contact with the immune complexes a molecule that specificially prevents Fc receptor expression at the membrane of the cells.
- the present invention relates to a method of inhibiting the binding of immune complexes (eg, IgG-containing immune complexes) present in a mammal to membrane-bound Fc receptors.
- the method comprises introducing into the mammal a soluble Fc receptor that competes with the membrane-bound Fc receptor for binding to the immune complex.
- the introduction is effected under conditions such that binding of the immune complex to the membrane-bound Fc receptor is inhibited.
- the present invention relates to a method of inhibiting the phagocytic potential of a mammalian cell bearing an Fc receptor.
- the method comprises introducing into the cell a construct comprising, in the 5'-3' direction of
- transcribed strand of which comprises a sequence complementary to endogenous mRNA encoding the Fc receptor
- a termination sequence functional in the cell iii) a termination sequence functional in the cell.
- the construct is introduced under conditions such that the complementary strand is transcribed and binds to the endogenous mRNA thereby reducing
- Figure 1 shows a schematic representation of
- Fc ⁇ RIIIA ⁇ wild type and mutants Shown above the schematic diagram of the ⁇ chain are signal sequence (S), external peptides (E), transmembrane domain (TM), and cytoplasmic domain (CY).
- S signal sequence
- E external peptides
- TM transmembrane domain
- CY cytoplasmic domain
- the expanded area shows an area of the nucleotide sequence of the ⁇ chain containing the conserved motif.
- the murine ⁇ chain is shown.
- the conserved amino acids of the gene family of the ⁇ and ⁇ chain genes are denoted by the underline.
- the N-proximal tyrosine encoded by the TAC codon of the nucleotides 235-237 (Ra et al, J. Biol. Chem.
- FIGS 2A and 2B show binding and phagocytosis of IgG-sensitized RBCs (EA) by transfected COS-1 cells. Binding of EA by transfected COS-1 cells (left panel: A, C, E and G). Phagocytosis of EA by transfected COS-1 cells (right panel; B, D, F, and H). (A) and (B) : binding and phagocytosis of COS-1 cells transfected with Fc ⁇ RIIIA ⁇ and wild type ⁇ . Three of the
- phagocytosed RBCs shown with wild type ⁇ are marked by arrows in Figure (B), (C) and (D): transfectants containing ⁇ and ⁇ (MIA).
- Figure 3 shows tyrosine phosphorylation of the wild type and mutant ⁇ chains by in vi tro kinase assay.
- the ⁇ chain was immunoprecipitated with anti- ⁇ antisera from lysates of COS-1 transfectants.
- vi tro kinase assay The ⁇ chain was immunoprecipitated with anti- ⁇ antisera from lysates of COS-1 transfectants.
- phosphorylated samples were run on a 12.5% reducing SDS-PAGE gel. The gel was treated with IN KOH to remove phosphoserine and threonine, dried and the autoradiogram was examined after 4 days.
- lane 1 Sham transfectants with Fc ⁇ RIIIA- ⁇ and pSVL vector without ⁇ cDNA insert
- lanes 2 Fc ⁇ RIIIA ⁇ + wild type human ⁇ .
- lane 3 Fc ⁇ RIIIA ⁇ + wild type mouse ⁇ .
- lane 4 Fc ⁇ RIIIA ⁇ + MIA.
- lane 5 Fc ⁇ RIIIA ⁇ + M2A.
- lane 6 Fc ⁇ RIIIA ⁇ + DMA.
- the phosphorylated ⁇ chains are denoted by an arrow (shown on the lower right side). The arrow with an asterisk (shown on the upper right side) is a specific tyrosine phosphoprotein band at approximately 40 kDa.
- Figures 4A-4D are a Ca 2+ mobilization following Fc ⁇ RIIIA stimulation. Measurement of [Ca 2+ ]i in individual cells was carried out during crosslinking of Fc ⁇ RIIIA. The time points when anti-Fc ⁇ RIII mAb, epinephrine (positive control) and calcium ionophore were added are denoted by arrows in each figure.
- transfectants were greatly decreased compared to WT transfectants.
- the present invention relates, at least in part, to methods of modulating the clearance from a mammal (eg, from the circulation of a mammal) of antibody-coated cells.
- the invention provides methods of treating immunologic disorders, such as autoimmune diseases, characterized by interactions of immune complexes (eg, IgG-containing immune complexes) with Fc receptors (for example, those present on the surface of macrophage), and immune mediated diseases such as asthma.
- the methods of the invention result in Fc receptor expression and/or function being altered so that phagocytosis of IgG antibody-coated cells is reduced.
- the invention provides methods of inhibiting Fc receptor function by inhibiting the phosphorylation of Fc receptor components that is required for phagocytic signal transduction and by introducing into the circulation soluble Fc receptors that compete with the membrane bound receptor for immune complex (eg, IgG-containing immune complex) binding.
- the invention also provides a method of inhibiting expression of Fc receptors by introducing into receptor-producing cells Fc receptor antisense constructs.
- the invention also provides methods of degrading Fc receptor RNA using, for example,
- the present invention relates to a method of preventing ingestion (eg phagocytosis) of immune complexes (eg IgG-coated cells) by inhibiting phosphorylation of core sequences within the
- cytoplasmic domains of the ⁇ and C chains of FcRIIIA is required for phagocytic signal transduction (the numbers following the letter X denote the number of amino acids at that position; X can be any amino acid but X2 within a Y-X2-L is preferably the amino acids present in a Y-X2-L sequence of the cytoplasmic domain of Fc ⁇ RIIA or the ⁇ chain of Fc ⁇ RIII). It appears that the second Y-X2-L of these core sequences (motifs) is particularly important for phagocytosis.
- the present invention contemplates the introduction into target cells of an inhibitor of the kinase(s) responsible for phosphorylation. In a specific embodiment, the
- inhibitor is a peptide that includes a sequence similar to, if not identical to, at least a functional portion of a tyrosine-containing motif (note, for example, the underlined portions of the motifs set forth above) and thus serves as a competitive inhibitor of the
- the inhibitor can take the form of an Fc receptor devoid of the extracellular domain or devoid of the extracellular and transmembrane domains.
- the inhibitor can be
- phosphorylation competitively or non-competitively eg, a mimetic of the active peptide can be used having a structural conformation similar to the binding site of the active peptide.
- the sequences of the ⁇ chain of Fc ⁇ RI necessary for mediator release eg, histamine, cytokines and leukotrienes
- mediator release eg, histamine, cytokines and leukotrienes
- the peptide inhibitor of the invention can be introduced into target cells directly, for example, using liposomes.
- liposomes See also approaches described in Science 26:1877 (1993) for administration of peptides modified so as to render them capable of crossing cellular lipid membranes.
- a DNA sequence encoding the peptide inhibitor can be introduced using gene therapy protocols so that the peptide is produced intracellularly.
- the inhibitor or inhibitor encoding sequence can be administered to the cells of the lung, including macrophages, in the form of an aerosol.
- the inhibitor or inhibitor encoding sequence can be present in the aerosol as a particle (e.g. liposome, or non-infectious bacteria, for example, Listeria, in the case of the encoding sequence) that is phagocytosed by the particle.
- Viral vectors can also be used to introduce the peptide inhibitor encoding sequence of the invention into cells of the pulmonary tree.
- the vectors can be introduced as an aerosol and can take the form of a replication defective herpes or adenoviral vector. Retroviral vectors can also be used. (See, generally, Bajocchi et al, Nat. Genet. 3:229 (1993); Lemarchand et al, Circ. Res., 72:1132 (1993); Ram et al, Cancer Res. 53:83 (1993); Crystal, Am. J. Med.
- Blood monocytes can be transformed (infected) ex vivo with the peptide inhibitor encoding sequence of the invention and then reintroduced into the patient so that the inhibitor is produced in vivo .
- phosphorylation involves the use of ribozymes that recognize RNA sequences specifying Fc receptor
- ribozyme can be effected using a carrier such as a liposome coated with IgG so as to direct insertion to Fc ⁇ receptor bearing cells.
- IgE-coated liposomes can be used to direct the ribozyme to mast cells or basophiles, or cells of that lineage, bearing the IgE receptor Fc ⁇ RI with its associated ⁇ subunit.
- the ⁇ subunit of the IgE receptor is responsible for transmitting the signal inducing the release of intracellular mediators by mast cells .
- the destruction of the ⁇ chain RNA is predicted to inhibit the release of these bioactive products.
- ribozymes administered as described would bind to a few selected sequences (eg, RNA splicing and 5' untranslated sequences for which they were specific, for example, in Fc ⁇ RIIA RNA or Fc ⁇ RIIIA ⁇ chain RNA) and the enzymatic activity associated with the ribozyme would result in digestion and thus removal of the RNA specifying functional sequences of the receptor necessary for phagocytic signal transduction.
- RNA sequences specifying the sequences of the ⁇ chain of Fc ⁇ RI necessary for mediator release eg, histamine, cytokines and leukotrienes
- phosphorylation involves the use of an antisense construct or ribozyme that targets Syk encoding
- the Syk gene product but not the gene product of ZAP-70 of the Syk kinase family, has been shown to stimulate Fc ⁇ RI and Fc ⁇ RIIIA phagocytosis mediated by both the ⁇ and ⁇ chains.
- Syk dependent phosphorylation can be effected.
- Constructs and ribozymes suitable for use in this method can be readily selected by one skilled in the art (see Yagi et al, Biochem. Biophys. Res. Comm. 200:28 (1994) for Syk gene sequence).
- the present invention relates to a method of inhibiting the interaction between immune complexes (eg, IgG-containing immune complexes) and membrane-associated Fc receptors and thereby suppressing the clearance of such complexes by phagocytosis (alternatively, the signalling through the Fc receptor resulting in the release of intracellular mediators).
- the method involves introducing into the circulation a soluble form of the Fc receptor that competes with the membrane bound form for immune complex binding. Transcripts of certain soluble forms have been identified in cells of megakaryocytic and monocyte/myeloid lineages (Rappaport et al, Exp.
- the present invention contemplates the production and use of soluble Fc receptors that include an extracellular domain alone or in combination with a cytoplasmic domain. Suitable receptors are capable of competing with membrane bound Fc receptors for binding of IgG-coated cells.
- Soluble receptors of the invention can take the form of Fc ⁇ RI, Fc ⁇ RII or Fc ⁇ RIII extracellular domains alone or binding portions thereof (alternatively, a soluble receptor of Fc ⁇ RI can be employed taking the form of an extracellular domain alone or binding portion thereof). As noted above, cytoplasmic domains, or portions thereof, can also be present.
- Fc ⁇ RIIA Fc ⁇ RIIA, respectively, and where ⁇ and ⁇ correspond to the ⁇ and ⁇ chains of Fc ⁇ RIII, the first designation indicating the source of the extracellular domain and the second the source of the cytoplasmic domain: I:I, I, IIA, IIA:IIA, I: IIA, ⁇ : ⁇ , ⁇ , ⁇ :IIA, I: ⁇ .
- Soluble receptors depending on their nature, can be prepared chemically or recombinantly (Horton et al, Biotechniques 8:528 (1990)).
- the soluble receptors can be administered systemically or to the lung as
- the present invention relates to a method of inhibiting Fc receptor
- an antisense construct comprising, in the 5'-3' direction of transcription: i) a promoter functional in the cells, ii) a segment of double-stranded DNA, the transcribed strand of which includes a sequence complementary to the endogenous mRNA of the Fc receptor the expression of which is to be inhibited, and iii) a termination sequence functional in the host cells.
- This embodiment of the invention makes it possible to regulate the expression of a specific Fc receptor in cells producing multiple receptor classes. This specificity can be achieved by selecting for inclusion in the DNA segment ((ii) above) sequences unique to the mRNA of the endogenous Fc receptor.
- sequence complementary to the endogenous Fc receptor mRNA is at least 15 nucleotides in length, preferably, at least 30 and, most preferably, at least 50.
- the sequence is typically less than 5000
- nucleotides in length preferably less than 2000, and most preferably less than 1000.
- sequence can be complementary to a translated or untranslated region of the mRNA (see, for example, McKenzie et al, Molec.
- antisense construct for example, to the lung and to the spleen, can be carried out as described above using both in vivo and ex vivo transformation protocols.
- antisense transcript itself can be introduced directly into the target cells using methods known in the art, including those described above.
- the present invention also relates to a method of effecting inhibition by introducing into a cell having phagocytic potential Fc ⁇ RIIB (eg Fc ⁇ RIIB2), which is capable of inhibiting the function of Fc ⁇ receptors, including Fc ⁇ RIIA.
- Fc ⁇ RIIB eg Fc ⁇ RIIB2
- Introduction of Fc ⁇ RIIB can be effected by transfecting/transforming a target cell with a construct comprising a sequence encoding Fc ⁇ RIIB, or portion thereof that effects the inhibition (Brooks et al, J. Exp. Med. 170:1369 (1989); Indik et al, Blood 83:2072 (1994)).
- Suitable constructs can be selected by one skilled in the art.
- Recombinant soluble Fc ⁇ RIII proteins can be produced using expression vectors as described below.
- the soluble protein can correspond to Fc ⁇ RIII with the transmembrane domain removed.
- the constructs can be introduced into mammalian cells under conditions such that expression of the receptor encoding sequence occurs.
- the recombinant proteins thus produced are isolated both from the cell lysates and from the supernatants.
- Transfection of adherent cells or cells in suspension Transfection of adherent cells, eg, CHO cells or COS cells, or an appropriate suspension cell system will be performed. Permanent transfectants expressing soluble forms of Fc ⁇ receptor will be established by
- Transfected cells will be allowed to grow 48 hours and selected in media containing Geneticin at 2 mg/ml (Gibco BRL, Gaithersburg, Maryland) or other selection drug. After approximately twelve weeks, positive colonies will be isolated and expanded for further characterization of the clones. The isolated clones will be examined by enzyme-linked immunoassay (ELISA) using ELISA plates (Dynatech, Alexandria, Virginia) to select a transfectant cell line expression the highest quantity of the soluble receptor. Mass culture of adherent transfectants will be achieved by employing the hollow-fiber tissue culture system.
- ELISA enzyme-linked immunoassay
- soluble Fc ⁇ RIII proteins are assessed both in vi tro and in vivo .
- the effect of soluble Fc receptors on IgG-immune complex binding to cellular membrane-bound receptors depends on several factors including the local concentrations of the ligand and soluble receptor, the surface density of the membrane-bound receptor, the valence of the ligand and the relative affinities of the two receptor forms for ligand.
- the limiting factors in the interaction of soluble Fc ⁇ RIII receptors with ligand and cellular membranes can be deciphered using available model systems.
- the in vi tro assay systems rely on the competition of soluble receptors with cell membrane receptors for labeled IgG ligand and IgG-coated erythrocytes (EA). Fc ⁇ receptor-negative cells are transfected with transmembrane Fc ⁇ RIII molecules that retain the
- Fc ⁇ RIII is also examined in vivo .
- an established experimental animal model is used to study whether soluble Fc ⁇ RIII administered in vivo alters the clearance of antibody coated cells (Ruiz and Schreiber, J. Clin. Invest. 88:149 (1991)).
- the immunoregulatory potential of soluble Fc ⁇ RIII is examined in this manner.
- the pSVL eucaryotic expression vector (Pharmacia LKB, Piscataway, NJ) was employed for expression of Fc ⁇ RIIIA in COS-1 cells.
- huFc ⁇ RIIIA ⁇ cDNA was cloned into the Xbal and BamHI cloning sites of pSVL.
- muFc ⁇ RIIIA ⁇ cDNA was cloned into Xhol and BamHI cloning sites.
- TCR/Fc ⁇ RIIIA ⁇ was cloned into the Xbal and BamHI cloning sites of pSVL.
- the transfection buffer containing DNA was added to COS-1 cells with incubation for 4 hours at 37°C. Cells were then shocked with 10% DMSO in phosphate buffered saline (PBS) for 2 minutes, washed twice with DMEM and grown in NuSerum supplemented DMEM. Cells were studied 48 hours following transfection.
- PBS phosphate buffered saline
- Transfected cells were harvested with staining buffer (PBS containing 0.02 % sodium azide and 0.1% BSA) using transfer pipettes. Cells were
- EA Sterile sheep red blood cells (10 9 /ml) in calcium and magnesium-free PBS were sensitized by incubation with an equal volume of a subagglutinating titer of rabbit anti-sheep RBC antibody (Cappel
- RBCs (EA) were washed twice with PBS and resuspended to a final concentration of 10 9 /ml for overlaying on transfected COS-1 cells. Cells were examined for rosetting ( ⁇ 10 EA per COS-1 cell) and phagocytosis as described previously (Indik et al, J. Clin. Invest.
- COS-1 cells bound with EA (after three washings) were subjected to a brief hypotonic shock (35 seconds) with hypotonic PBS to remove surface bound EA. The cells were then stained with Wright-Giemsa staining
- Inhibitors of phosphatases and proteases (ImM EGTA, 1 mM Na orthovanadate, 1 mM PMSF, 10 ⁇ g/ml aprotinin, 50 ⁇ g/ml leupeptin, and 100 ⁇ g/ml soybean trypsin inhibitor) were added fresh to lysis buffer. After 15 minutes of lysis on ice, cell lysates were centrifuged for 30 minutes at 4°C to clarify. The
- Fc ⁇ RIIIA- ⁇ chain was immunoprecipitated with anti-human ⁇ antiserum (provided by Jean-Pierre Kinet, NIAID-NIH, Rockville, MD) and Protein A-sepharose CL4B (Signa, St. Louis, MO) in lysis buffer. Pellets were washed three times in lysis buffer and once in low salt buffer (100 mM NaCl, 25 mM Hepes, pH 7.4 and 5 mM MnCl 2 ).
- Pellets were incubated (20°C, 10 min.) with 30 ⁇ l of a mixture containing 25 mM Hepes, pH 7.4, 5 mM MnCl 2 , 5 mM p-nitrophenyl-phosphate, 1 ⁇ M cold ATP (Boehringer
- COS-1 cells plated on glass coverslips were incubated with 2 ⁇ M Fura-2/AM (Calbiochem. San Diego, CA) for 30 minutes, washed twice and the coverslips then
- Fc ⁇ RIIIA receptors were crosslinked either with biotinylated anti-Fc ⁇ RIII followed by the addition of streptavidin or with anti-Fc ⁇ RIII mAB 3G8 whole IgG.
- 10 ⁇ M epinephrine was added to crosslink epinephrine receptors expressed on COS cells.
- Calcium imaging was performed using a 40x fluorescence objective on a Nikon Diaphot microscope with the image- 1 AT quantitative fluorescence system (Universal
- 340/380 ratio images were calculated on a pixel by pixel basis and the average 340/380 ratio within each cell determined at each time point. 340/380 ratios were converted to [Ca 2+ ]i based on solution
- FMI mean fluorescence intensity
- cotransfected cells stained with anti-Fc ⁇ RIII mAB increased by 15 fold compared to cells stained with an IgG isotype control or compared to mock-transfected cells stained with anti-Fc ⁇ RIII mAB (Table 1).
- the transfectants were examined for their ability to bind and phagocytose IgG sensitized RBCs (EA).
- results summarized in Table 2 are as follows: M1 ⁇ mutants showed more than 99% reduction in phagocytic activity as shown by phagocytic index (PI) ( ⁇ 1 % of transfectants with ingested EA and minimal ingested EA per phagocytosing cell) (p ⁇ 0.02); M2 and DM ⁇ mutants demonstrated essentially no phagocytosis (1 among 5000 cells examined) (Table 2, Fig. 2).
- PI phagocytic index
- the in vi tro kinase assay demonstrated a distinct band of approximately 40 kDa present in all lanes except the sham transfectants. This band may represent an associated phosphoprotein coprecipitating with ⁇ .
- Fc ⁇ RIII in its native state on pulmonary macrophage or cultured monocytes (M) was examined in order to study the physiologically relevant protein tyrosine kinases (PTK) and phosphotyrosine containing substrates during macrophage signal transduction.
- PTK protein tyrosine kinases
- Fab antibody Western blot analysis revealed a characteristic pattern of
- Phosphotyrosine patterns were indistinguishable in fresh macrophage and cultured monocytes, validating the latter as a useful in vi tro model.
- P62 a protein associated with p120 ras GAP, although not GAP itself, was identified by specific immunoprecipitation as one of these phosphotyrosine substrates.
- a second substrate was found to be p95 vav , a hematopoietic oncogene product which is also tyrosine phosphorylated after TCR, slg and Fc ⁇ RI activation.
- the kinase PTK72/Syk heretofore identified only in B cell slg and mast cell Fc ⁇ RI signaling, was also a major phosphotyrosine substrate after macrophage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Sorption Type Refrigeration Machines (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2172392A CA2172392C (fr) | 1993-09-30 | 1994-09-30 | Methode d'inhibition de la phagocytose |
AU79244/94A AU701919B2 (en) | 1993-09-30 | 1994-09-30 | Methods of inhibiting phagocytosis |
EP94929970A EP0723455B1 (fr) | 1993-09-30 | 1994-09-30 | Methode d'inhibition de la phagocytose |
DE69432472T DE69432472D1 (de) | 1993-09-30 | 1994-09-30 | Verfahren zur hemmung der phagozytose |
AT94929970T ATE236650T1 (de) | 1993-09-30 | 1994-09-30 | Verfahren zur hemmung der phagozytose |
JP7510472A JPH09506072A (ja) | 1993-09-30 | 1994-09-30 | 食作用を阻害する方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12938193A | 1993-09-30 | 1993-09-30 | |
US129,381 | 1993-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995009002A1 true WO1995009002A1 (fr) | 1995-04-06 |
Family
ID=22439683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/011108 WO1995009002A1 (fr) | 1993-09-30 | 1994-09-30 | Methode d'inhibition de la phagocytose |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0723455B1 (fr) |
JP (2) | JPH09506072A (fr) |
AT (1) | ATE236650T1 (fr) |
AU (1) | AU701919B2 (fr) |
CA (1) | CA2172392C (fr) |
DE (1) | DE69432472D1 (fr) |
IL (1) | IL111105A (fr) |
WO (1) | WO1995009002A1 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996037605A3 (fr) * | 1995-05-26 | 1996-12-27 | Scras | OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE |
JPH11507824A (ja) * | 1995-06-07 | 1999-07-13 | ユニバーシティー・オブ・ペンシルバニア | 食作用を阻害する方法 |
WO1999041285A1 (fr) * | 1998-02-17 | 1999-08-19 | Medarex, Inc. | Traitement et diagnostic des maladies dues aux macrophages au moyen des ligands des recepteurs de fc |
EP1006183A1 (fr) * | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Récepteurs Fc recombinantes et solubles |
US6638764B2 (en) | 1993-09-30 | 2003-10-28 | University Of Pennsylvania | Methods of inhibiting phagocytosis |
EP1346218A4 (fr) * | 2000-11-22 | 2006-03-15 | Univ Pennsylvania | Tripeptide de fc gama riia |
US7192615B2 (en) | 2001-02-28 | 2007-03-20 | J&J Consumer Companies, Inc. | Compositions containing legume products |
US7309688B2 (en) | 2000-10-27 | 2007-12-18 | Johnson & Johnson Consumer Companies | Topical anti-cancer compositions and methods of use thereof |
US7985404B1 (en) | 1999-07-27 | 2011-07-26 | Johnson & Johnson Consumer Companies, Inc. | Reducing hair growth, hair follicle and hair shaft size and hair pigmentation |
US8039026B1 (en) | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
US8093293B2 (en) | 1998-07-06 | 2012-01-10 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin conditions |
US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686282A (en) * | 1983-08-12 | 1987-08-11 | Immunetech, Inc. | Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5189014A (en) * | 1979-12-03 | 1993-02-23 | Cowan Jr Fred M | Method of treating cellular Fc receptor mediated hypersensitivity immune disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991006570A1 (fr) * | 1989-10-25 | 1991-05-16 | The University Of Melbourne | MOLECULES RECEPTRICES Fc HYBRIDES |
US5770396A (en) * | 1992-04-16 | 1998-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E |
FR2702481B1 (fr) * | 1993-03-09 | 1995-04-28 | Roussel Uclaf | Nouveaux récepteurs Fc-gamma III humains solubles, leur procédé de préparation, les compositions pharmaceutiques les contenant, leur application comme médicaments et leur application diagnostique. |
-
1994
- 1994-09-29 IL IL111105A patent/IL111105A/en not_active IP Right Cessation
- 1994-09-30 JP JP7510472A patent/JPH09506072A/ja active Pending
- 1994-09-30 AT AT94929970T patent/ATE236650T1/de not_active IP Right Cessation
- 1994-09-30 WO PCT/US1994/011108 patent/WO1995009002A1/fr active IP Right Grant
- 1994-09-30 AU AU79244/94A patent/AU701919B2/en not_active Ceased
- 1994-09-30 EP EP94929970A patent/EP0723455B1/fr not_active Expired - Lifetime
- 1994-09-30 DE DE69432472T patent/DE69432472D1/de not_active Expired - Lifetime
- 1994-09-30 CA CA2172392A patent/CA2172392C/fr not_active Expired - Fee Related
-
2006
- 2006-04-25 JP JP2006120929A patent/JP2006217922A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189014A (en) * | 1979-12-03 | 1993-02-23 | Cowan Jr Fred M | Method of treating cellular Fc receptor mediated hypersensitivity immune disorders |
US4686282A (en) * | 1983-08-12 | 1987-08-11 | Immunetech, Inc. | Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
Non-Patent Citations (5)
Title |
---|
BLOOD, Volume 77, No. 3, issued 01 February 1991, W. AKERLEY III et al., "Neutrophil Activation Through High-Affinity Fc gamma Receptor Using a Monomeric Antibody with Unique Properties", pages 607-615. * |
JOURNAL OF IMMUNOLOGY, Volume 150, No. 8, Part II, 1754, issued 15 April 1993, Z. INDIK et al., "Examination of Phagocytosis by Chimeric Fc gamma Receptors", page 306A. * |
ONCOGENE, Volume 1, issued 1987, O. SHOHAT et al., "Inhibition of Cell Growth Mediated by Plasmids Encoding p53 Anti-Sense", pages 277-283. * |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 268, No. 21, issued 25 July 1993, A. AGARWAL et al., "Involvement of p72syk, A Protein-Tyrosine Kinase, in Fc gamma Receptor Signaling", pages 15900-15905. * |
TIBTECH, Volume 8, issued July 1990, J. ROSSI et al., "RNA Enzymes (Ribozymes) as Antiviral Therapeutic Agents", pages 179-183. * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638764B2 (en) | 1993-09-30 | 2003-10-28 | University Of Pennsylvania | Methods of inhibiting phagocytosis |
US7148014B2 (en) | 1993-09-30 | 2006-12-12 | University Of Pennsylvania | Methods of inhibiting phagocytosis |
US5892023A (en) * | 1995-05-26 | 1999-04-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Anti sense oligonucleotides for blocking IgE receptor synthesis |
WO1996037605A3 (fr) * | 1995-05-26 | 1996-12-27 | Scras | OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE |
JPH11507824A (ja) * | 1995-06-07 | 1999-07-13 | ユニバーシティー・オブ・ペンシルバニア | 食作用を阻害する方法 |
EP0831875A4 (fr) * | 1995-06-07 | 2002-07-31 | Univ Pennsylvania | Procedes d'inhibition de la phagocytose |
US8039026B1 (en) | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
WO1999041285A1 (fr) * | 1998-02-17 | 1999-08-19 | Medarex, Inc. | Traitement et diagnostic des maladies dues aux macrophages au moyen des ligands des recepteurs de fc |
US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
US8093293B2 (en) | 1998-07-06 | 2012-01-10 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin conditions |
US8666680B2 (en) | 1998-12-03 | 2014-03-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble FC receptors |
US7074896B1 (en) | 1998-12-03 | 2006-07-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
WO2000032767A1 (fr) * | 1998-12-03 | 2000-06-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | RECEPTEURS SOLUBLES DE RECOMBINAISON DU Fc |
EP1006183A1 (fr) * | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Récepteurs Fc recombinantes et solubles |
US7985404B1 (en) | 1999-07-27 | 2011-07-26 | Johnson & Johnson Consumer Companies, Inc. | Reducing hair growth, hair follicle and hair shaft size and hair pigmentation |
US7309688B2 (en) | 2000-10-27 | 2007-12-18 | Johnson & Johnson Consumer Companies | Topical anti-cancer compositions and methods of use thereof |
US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
US7087585B2 (en) | 2000-11-22 | 2006-08-08 | The Trustees Of The University Of Pennsylvania | Tripeptide of FcγRIIA |
EP1346218A4 (fr) * | 2000-11-22 | 2006-03-15 | Univ Pennsylvania | Tripeptide de fc gama riia |
US7897144B2 (en) | 2001-02-28 | 2011-03-01 | Johnson & Johnson Comsumer Companies, Inc. | Compositions containing legume products |
US7192615B2 (en) | 2001-02-28 | 2007-03-20 | J&J Consumer Companies, Inc. | Compositions containing legume products |
Also Published As
Publication number | Publication date |
---|---|
DE69432472D1 (de) | 2003-05-15 |
EP0723455A1 (fr) | 1996-07-31 |
JP2006217922A (ja) | 2006-08-24 |
CA2172392A1 (fr) | 1995-04-06 |
IL111105A (en) | 2009-05-04 |
EP0723455A4 (fr) | 1999-09-01 |
IL111105A0 (en) | 1994-11-28 |
ATE236650T1 (de) | 2003-04-15 |
CA2172392C (fr) | 2011-06-21 |
EP0723455B1 (fr) | 2003-04-09 |
AU7924494A (en) | 1995-04-18 |
AU701919B2 (en) | 1999-02-11 |
JPH09506072A (ja) | 1997-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5858981A (en) | Method of inhibiting phagocytosis | |
JP2006217922A (ja) | 食作用を阻害する方法 | |
US5641863A (en) | Chimeric IgG Fc receptors | |
US8784814B2 (en) | Method for inhibiting binding to B-cell receptor | |
JPH04502859A (ja) | 内皮細胞―白血球付着分子(elam)および白血球付着に関与する分子(mila) | |
CA2223402C (fr) | Procedes d'inhibition de la phagocytose | |
Indik et al. | Structure/function relationships of Fcγ receptors in phagocytosis | |
Davidson et al. | Distribution and immunoregulatory properties of antisecretory factor | |
WO1996040199A9 (fr) | Procedes d'inhibition de la phagocytose | |
US6630313B2 (en) | Phosphatidyl serine receptors and uses thereof | |
US5804189A (en) | Treatment of lipopolysaccharide- or CD14-mediated conditions using soluble CD14 | |
SK170497A3 (en) | Cytoplasmic modulators of integrin regulation/signaling | |
EP0650367A1 (fr) | Blocage des interactions intercellulaires avec des molecules chimeriques cd43 | |
Lee | Proteomic and functional characterisation of LILRA3: Role in inflammation | |
JP2003212791A (ja) | ラミニン−6を含む、細胞接着活性及び/又は細胞運動活性調節用組成物 | |
JPH1072495A (ja) | 免疫関連因子 | |
AU1204799A (en) | Viral encoded semaphorin protein receptor dna and polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2172392 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994929970 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994929970 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994929970 Country of ref document: EP |